Table 1.
Baseline Measurements in Participants Who Completed the Study
| Placebo | Losartan | p Value | |
|---|---|---|---|
| N = 15 | N = 10 | ||
| Physical measurements* | |||
| Age (years) | 78.1 (6.3) | 75.1 (5.0) | .22 |
| Sex | .44 | ||
| Male Female |
10 (66.7) 5 (33.3) |
5 (50.0) 5 (50.0) |
|
| Systolic blood pressure (mmHg) | 138.2 (16.9) | 139.4 (21.1) | .88 |
| Diastolic blood pressure (mmHg) | 73.6 (12.5) | 72.1 (12.5) | .77 |
| Heart rate (beats per minute) | 70.6 (11.4) | 63.2 (5.8) | .062 |
| Body mass index (kg/m2) | 27.3 (5.0) | 30.2 (4.4) | .14 |
| Dominant-hand grip strength (kg) | 21.9 (7.1) | 24.1 (9.9) | .55 |
| Walking speed (m/sec) | 1.1 (0.2) | 1.1 (0.2) | .73 |
| Six minute walk (m) | 435.9 (132.9) | 423.0 (80.6) | .78 |
| Biodex both knee max strength (N) | 77.7 (27.6) | 85.9 (39.1) | .54 |
| Chemistry lab values* | |||
| Potassium (mEq/L) | 4.1 (0.4) | 4.2(0.4) | .53 |
| Blood urea nitrogen (mg/dL) | 16.4 (4.2) | 19.4 (6.9) | .20 |
| Creatinine (mg/dL) | 1.0 (0.2) | 1.0 (0.3) | .66 |
| Chloride (mEq/L) | 104.4 (2.8) | 105.8 (1.6) | .14 |
| Carbon dioxide(mmol/L) | 28.1 (2.5) | 27.7 (2.1) | .67 |
| Aspartate aminotransferase (IU/L) | 18.8 (3.6) | 22.2 (10.6) | .27 |
| Alanine aminotransferase (IU/L) | 22.9 (6.8) | 32.0 (19.3) | .11 |
| Albumin (g/dL) | 3.8 (0.9) | 3.9 (0.3) | .46 |
| Total bilirubin (mg/dL) | 0.7 (0.6) | 0.7 (0.3) | .78 |
| Inflammatory lab values** | |||
| Interleukin-1β (pg/mL) | 24.1 (11.6–84.1) | 20.4 (14.0–88.8) | .61 |
| Tumor necrosis factor-α (pg/mL) | 3.8 (2.1–10.2) | 2.9 (2.2–6.5) | .25 |
| Tumor necrosis factor-α receptor 1 (pg/mL) | 1 313.7 (713.4–2344.8) | 1 189.1 (633.0–1785.0) | .57 |
Notes:
*Data are presented as the means (standard deviation [SD]) for continuous measures.
**Data are presented as the medians (interquartile ranges [IQRs]) for continuous measures.